Clinical Trial Update: An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial evaluating high-dose Glivec (imatinib) in chronic myeloid leukemia in chronic phase using molecular endpoints; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Glivec (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: CML, Imatinib | Phase 2 | Status: COMPLETED